Hadassah

Hadassah Ophthalmology’s X-Factor Discovery: Celebrating Its Impact

Monday, Jul 30 2018

Prof. Jacob Pe'er

Imagine that it is 1948. Dr. Isaac Caesar Michaelson, who served as an ophthalmic surgeon for the British Eighth Army while its soldiers fought the Nazis in Egypt, immigrates to Israel.

He is asked by the newly created health ministry to set up eye-care services for the new state.

Six years later, in 1954, Prof. Michaelson is named the Director of the Hadassah Medical Center’s Ophthalmology Department.

Under his management, the department becomes the Ophthalmology Research Center--the first department of ophthalmology to include research laboratories. Prof. Michaelson zeroes in on pathological new blood vessel formation in the retina and predicts that there is a protein that is triggering this abnormal vessel growth. He names it “the x-factor.” While this factor was considered essential for the development of the retina’s blood vessels, it could also stimulate the creation of too many vessels in response to a lack of oxygen reaching the retinal tissues and cause various retinal diseases.

Fast forward to 1991. Hadassah Ophthalmologist Prof. Jacob Pe’er is studying ocular cancer. He goes to see Prof. Eli Keshet, a molecular biologist at the Hadassah-Hebrew University Medical School, because he knew the professor was studying the mechanisms of blood vessel formation and the elaborate controls of the main protein that initiates the genesis of new blood vessels. These blood vessels are a most important factor in nourishing cancer cells.

As he listens to Prof. Keshet describe his work, Prof. Pe’er finds that his heart is beginning to race. He urges Prof. Keshet to examine a retinal tissue sample from one of his cancer patients because he suspects that the protein Prof. Keshet is studying is Prof. Michaelson’s x-factor.

Recalling this scenario all these many years later, Prof. Pe’er says, "I couldn't sleep for three nights until the results came back. Sure enough, we had found the key to Michaelson’s mysterious x-factor. Now a medicine could be developed to treat it and save eyesight.”

That protein is called Vascular Endothelial Growth Factor (VEGF). It is a signal protein that stimulates the formation of blood vessels. With this discovery, the intellectual door was opened for a drug manufacturer named Genentech to develop an antidote for this overproductive VEGF.

Genentech’s Avastin--one of the most widely prescribed medicines today to treat such retinal diseases as age-related macular degeneration, diabetic retinopathy, and central retinal vein occlusion-- was the result.

Prof. Pe’er explains, "It's simple. The key to developing any medication is first identifying the germ or bacteria or, in this case, a protein that is causing the problem. Once we identified the VEGF, the drug company could develop its remedy. Avastin is the 'anti' that combats the overproducing VEGF.”

Today, there are a number of “anti-VEGF” drugs being studied to treat a variety of cancers.

Learn more about the Hadassah Medical Organization.

Comments

No comments yet.
First Name
Email
Comment
Enter this word:

Related Stories

alt_text

Monday, Aug 20 2018

Delicate Cataract Surgery Performed by Hadassah Hospital Specialist

Dr. Charlotte Slopak Goller had suffered from bad vision her whole life. As a child, she found herself constantly needing thicker and thicker glasses. Only in high school did an optometrist correctly diagnose her condition as keratoconus, a disorder that results in progressive thinning of the cornea.

READ MORE ›
alt_text

Friday, Aug 17 2018

Hadassah Mourns the Loss of Aretha Franklin and Urges Greater Awareness of Diagnosis and Treatment of Pancreatic Cancer

Sadly, the “queen of soul” Aretha Franklin passed away yesterday at age 76, due to an advanced pancreatic neuroendocrine tumor (pancreatic NET or PNET).

READ MORE ›
alt_text

Wednesday, Aug 15 2018

Hadassah Hospital’s Bone Marrow Transplant Department Receives International Acclaim

In a first for Israel, Hadassah Medical Organization’s Bone Marrow Transplantation and Cancer Immunotherapy Department has recently received full accreditation by the Joint Accreditation Committee ISCT-EUROPE & EBMT (JACIE), Europe’s only official accreditation body in the field.

READ MORE ›
alt_text

Tuesday, Aug 14 2018

Hadassah Hospital Helps Educate Mikvah Attendants To Bolster Women’s Health

After a woman emerges from the ritual bath (mikveh) and wraps herself in a towel, says mikveh attendant Daniella Salomon, “I keep an eye out” for anything unusual.

READ MORE ›

Donation Questions

donorservices@hadassah.org

(800) 928-0685

Membership Questions

membership@hadassah.org

(800) 664-5646

Missions Department

missions@hadassah.org

(800) 237-1517

Contact Us

40 Wall Street

New York, NY 10005

support@hadassah.org

More ›

Show More